A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors

NCT02100696 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

609

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: Etrozulimab
DRUG: Placebo

Sponsor

Hoffmann-La Roche